Stroke

Cardiovascular departments are playing a role in stroke interventions at numerous health systems, working as part of the stroke care team with neurologists, radiology and the emergency department. Stroke first has be be classified as ischemic or hemorrhagic. These have very different care pathways. Ischemic strokes are increasingly being treated with neurological-interventional therapy that includes catheter based mechanical thrombectomy to remove the clot. This is a more aggressive treatment compared to traditional IV administration of tissue plasminogen activator (tPA) thrombolytic therapy to dissolve the clot. Subarachnoid hemorrhage (SAH) and  intracerebral hemorrhage (ICH) brain bleeds can also be treated in some cases stent flow diverters and embolization coils. 

RSS icon
Medtronic entered into an exclusive U.S. distribution agreement with Contego Medical for carotid and peripheral vascular disease revascularization products and includes option to acquire the company.

Medtronic expands carotid portfolio with Contego Medical deal

Medtronic entered into an exclusive U.S. distribution agreement with Contego Medical for carotid and peripheral vascular disease revascularization products. The agreement includes an option to acquire the full company at a later date. 

Thumbnail

Johnson & Johnson pauses use of FDA-approved PFA system to investigate patient complications

Johnson & Johnson MedTech's Varipulse PFA system has been linked to multiple reports of "neurovascular events" in patients. The company hopes to share more information in the days ahead. 

ACC offers practical approaches for arrhythmia monitoring after stroke

The American College of Cardiology published an expert consensus on practical approaches for arrhythmia monitoring after stroke to improve post-stroke care by identifying and managing atrial fibrillation.

older patient with a doctor at their house

‘Fundamental for all patients’: Exploring the benefits of palliative care for stroke survivors

Approximately 800,000 strokes occur each year in the United States alone. A majority of people survive, due in part to key advances in patient care over the years, but they often go forward without receiving the long-term help they need to recover and thrive. 

Left atrial appendage occlusion (LAAO) with the Watchman FLX device from Boston Scientific is associated with positive outcomes and limited adverse events after one year, according to new findings published in Circulation: Cardiovascular Interventions.[1] Many prior Watchman FLX studies, including PINNACLE FLX, had focused on the device’s performance in a controlled setting. The study’s authors hoped to gain a better understanding of its real-world impact by reviewing registry data from more than 97,000 U.S

LAAC with Watchman FLX reduces bleeding risks after AFib ablation

The new data, presented during AHA Scientific Sessions 2024, suggest LAAC with Boston Scientific's Watchman FLX could be a safe, effective alternative to OAC for limiting post-ablation strokes.

Contego Medical, a North Carolina-based medical device company, has received U.S. Food and Drug Administration (FDA) approval for its new all-in-one carotid stenting offering, the Neuroguard IEP System

FDA gives green light to 3-in-1 carotid stent system designed to limit strokes

The newly approved system includes a stent, dilation balloon and integrated embolic protection filter. After CMS expanded Medicare coverage for carotid artery stenting in 2023, the procedures are expected to grow more and more common as time goes on. 

COVID from a patient's nasal passage. Transmission electron micrograph of SARS-CoV-2 virus particles (gold) within endosomes of a heavily infected nasal olfactory epithelial cell. Image captured at the NIAID Integrated Research Facility (IRF) in Fort Detrick, Maryland. Image courtesy of NIAID. What does COVID look like?

History of COVID-19 doubles long-term risk of heart attack, stroke or death

A patient's blood type appears to play a major role in their odds of developing cardiovascular issues after COVID-19, researchers found. 

money business cash flow dollar

AstraZeneca spends up to $1.9B for new heart disease drug

Early data suggest the drug, an oral lipoprotein (a) disruptor, could make a significant impact on patient care. AstraZeneca will pay $100 million upfront, with much more to follow if certain milestones are met. 

Displaying 1 - 8 of 61

Around the web

Radiology Business
Key takeaways from RSNA 2024 for AI, CT, MRI and the radiology staffing shortage

Several key trends were evident at the Radiological Society of North America 2024 meeting, including new CT and MR technology and evolving adoption of artificial intelligence.

Health Imaging
Use of AI opportunistic screening in CT for cardiovascular disease

Ron Blankstein, MD, professor of radiology, Harvard Medical School, explains the use of artificial intelligence to detect heart disease in non-cardiac CT exams.